Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Sacituzumab Govitecan Prolongs OS in Heavily Pretreated HR+ Breast Cancer

August 15th 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful improvement in overall survival vs standard chemotherapy in patients with hormone receptor–positive, HER2-negative breast cancer who received prior treatment with endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy, according to findings from the second interim analysis of the phase 3 TROPiCS-02 trial.

Trastuzumab Deruxtecan Improves PFS, OS in T-DM1–Pretreated HER2+ Metastatic Breast Cancer

August 15th 2022

Trastuzumab deruxtecan led to a statistically significant improvement in progression-free survival and overall survival vs treatment with physician’s choice in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Future Directions in Care for HER2+ Breast Cancer

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

FDA Grants Priority Review to Elacestrant for ER+/HER2- Advanced or Metastatic Breast Cancer

August 11th 2022

The FDA has granted priority review to a new drug application seeking the approval of elacestrant for use in patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.

State of Science Summit- Breast Cancer: Chaired by Judy Boughey, MD and Matthew Goetz

August 11th 2022

State of Science Summit- Breast Cancer: Chaired by Judy Boughey, MD and Matthew Goetz

NCCN Elevates Sacituzumab Govitecan-Hziy to Preferred Recommendations in Metastatic Breast Cancer

August 10th 2022

Sacituzumab govitecan-hziy is now a category 1 preferred recommendation in triple-negative breast cancer and a category 2A preferred recommendation in HR-positive/HER2-negative disease.

Utilizing Brain MRI to Inform Treatment for HER2+ Metastatic Breast Cancer

August 10th 2022

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC

August 10th 2022

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Novel Treatment Strategies for HER2-Low Breast Cancer

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Establishing the Paradigm of HER2-Low Breast Cancer

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.